News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.

Firm News July 23, 2025
Gibson Dunn Represented XOMA Royalty in the Acquisition of ESSA Pharma by XenoTherapeutics
Gibson Dunn represented XOMA Royalty Corporation in connection with the acquisition of ESSA Pharma Inc. by XenoTherapeutics, Inc.
Client Alert July 17, 2025
Is There a Duty to Disclose FDA Feedback?
The Trustees of Welfare & Pension Funds of Local 464A – Pension Fund v. Medtronic PLC, 726 F. Supp. 3d 938 (D. Minn. 2024).
Firm News July 3, 2025
Gibson Dunn Represented HealthCare Royalty and Blue Owl Capital in Acquisition of BridgeBio Pharma’s Royalty Interest in Bayer’s BEYONTTRA®
Gibson Dunn advised HealthCare Royalty and Blue Owl Capital on their acquisition from BridgeBio Pharma of its royalty interest in Bayer’s BEYONTTRA® for $300 million.
Publications June 30, 2025
Royalty Finance Tracker
The Gibson Dunn team has represented clients in royalty finance transactions with a total aggregate value of approximately $8 Billion.
Accolades June 11, 2025
Gibson Dunn Ranked in 2025 U.S. Legal 500
Gibson Dunn earned 60 practice area rankings, including 17 top-tier rankings, in the 2025 edition of The Legal 500 – United States
Webcasts May 12, 2025
Gibson Dunn and BCLT Host a Webcast Series on Royalty Finance, the UCC, and Issues of Recharacterization
In a three-part virtual series, BCLT & Gibson Dunn have partnered to discuss issues originally raised in a Law 360 article written by Gibson Dunn attorneys, Todd Trattner and Ryan Murr, entitled How Biotech Cos. Can Utilize Synthetic Royalty Financing.
In the Media May 6, 2025
Gibson Dunn Partners Discuss Securities Law Issues Surrounding Reverse Merger Transactions in DealLawyers.com Podcast
Gibson Dunn partners Branden Berns, James Moloney, and Ryan Murr discussed current securities law issues surrounding reverse merger transactions in a recent DealLawyers.com podcast.
Firm News April 10, 2025
Gibson Dunn Launches Biotech Briefings Blog and New Royalty Finance Tracker to Provide Actionable Insights on Life Sciences Industry Trends
Gibson Dunn is pleased to announce the launch of Biotech Briefings, a new blog offering timely analysis and commentary on the legal, business, and regulatory issues shaping the life sciences industry.